Mannkind Corp (MNKD) has gained an incredible ~40% in the past 5 days as the biotech awaits FDA's final call on it's experimental inhaled insulin drug, Afrezza. The PDUFA is scheduled for Dec. 29, 2010.
The world of biotech is both exhilarating and rewarding. However, picking the appropriate companies to invest in can be challenging and at times depressing. In this blog, you will find information gathered from industry reports, analyst forecasts, and market trends, helping you to emerge from mindless speculation and make intelligent investment decisions! - Michael Juan
Wednesday, December 15, 2010
Saturday, December 11, 2010
Orexigen (OREX) - put options yielded 138% return since FDA advisory committee meeting
Orexigen`s December put options with $10 strike price were traded at $0.65 on the morning after the company`s met with the FDA`s advisory panel (Dec. 8, 2010) regarding Orexigen`s late phase obesity drug, Contrave. At one point the options skyrocketed to $1.90 before settling at $1.55 at Friday`s close. Because it was rightly predicted that OREX would come down significantly from the post-approval hype, those who purchased put options profited from the fall of OREX`s share value. So how much profit is that? Well, let's look at an example:
# of contracts purchased: 10 (options to sell 10 x 100 = 1,000 share)
Cost of purchase: $0.65 x 1000 = $650
Investment return: $1.55 x 1000 = $1,550
Net gain: $1,550 - $650 = $900
% gain: 138%
Not bad for 2 days of waiting? I certainly think so!
# of contracts purchased: 10 (options to sell 10 x 100 = 1,000 share)
Cost of purchase: $0.65 x 1000 = $650
Investment return: $1.55 x 1000 = $1,550
Net gain: $1,550 - $650 = $900
% gain: 138%
Not bad for 2 days of waiting? I certainly think so!
Thursday, December 9, 2010
Orexigen (OREX) - fat profit for short sellers (30% gain in 48 hrs)
| BEFORE - $12.42 (shown in 'after hours' price) |
| AFTER - 30% drop in 2 days (profit for short sellers) |
Once again, short selling pays. Orexigen has shed 30% of its post-advisory meeting peak value, $12.42, in just 2 days. This is mainly the result of a correction to the post-advisory meeting hype, which is observed almost always shortly after a huge catalyst passes.
Tuesday, December 7, 2010
Orexigen Therapeutics (OREX) - up 155% on FDA advisory panel vote (13 to 7) for approval of Contrave
~~~Breaking news~~~
What to do now?
SHORT the stock!!! Anticipate a 10-20% sell-off in the near future as investors scramble to cash out. Just like Mela Sciences (MELA), the spectacular rise in OREX right now is the result of market overreaction, which almost always evaporates sooner or later. Want some examples? Take a look at AVNR, DNDN and SOMX!!!
| Pre-approval run-up |
| Post-approval drop (-31%) |
Somaxon Pharmaceuticals (SOMX)
| Pre-approval run-up |
| Post-approval drop (-70%) |
Monday, December 6, 2010
Mela Sciences (MELA) - short sellers reap 33% profit from falling biotech
Mela Sciences (MELA) jumped a hefty 109% after receiving a 'not-all-completely negative' recommendation from FDA's advisory panel on Nov. 19, 2010. This is 48 hours post FDA's warning against Mela's experimental medical device and the alleged violation against federal securities laws by company executives. Spotting an overreaction by the market immediately after the close to split votes by the medical experts on the panel, goldbiopharma recommended that MELA was a ripe opportunity for short selling.
"MELA's shares more than doubled in pre-market trading. This may be a good opportunity to SHORT the stock as this overreaction is expected to wean in the next few weeks."
To date, the stock has fallen 33% - not a bad return in ~2 weeks for short sellers!!!
Tuesday, November 23, 2010
Two companies up despite market losses - MannKind (MNKD) and pSivida (PSDV)
Friday, November 19, 2010
ALERT - Mela Sciences (MELA) bounced back more than 100% post FDA advisory panel
Mela Sciences (MELA), developer of handheld skin cancer detector, received marginal support from FDA's advisory panel yesterday, boosting its share price back up over 100%. As mentioned in my previous post, anything is possible; the biotech may in fact receive 'non-negative' recommendations from the panel. The vote came out 8-7. Eight out of 15 medical specialists on FDA's advisory committee voted FOR the passing of MELA's device.
MELA's shares more than doubled in pre-market trading. This may be a good opportunity to SHORT the stock as this overreaction is expected to wean in the next few weeks.
Subscribe to:
Posts (Atom)

